Innovent Bio submitted the latest securities change monthly report on August 31, 2024, which showed that the number of common shares remained unchanged in August, with a total of 5,000,000,000 shares, and the total statutory/registered capital was $50,000. The number of issued shares (excluding treasury shares) experienced a slight change, increasing from 1,629,278,889 shares to 1,631,045,869 shares, an increase of 1,766,980 shares. In addition, the report noted that the company issued new shares in August through the exercise of stock options, including pre-IPO stock incentive plans, post-IPO employee share ownership plans, and the 2024 stock plan. The company also corrected some data errors in the previous monthly report. The report was submitted to Hong Kong Exchanges and Clearing Limited by joint company secretary Wang Yanju on September 6, 2024.

Innovent Bio submitted the latest securities change monthly report on August 31, 2024, which showed that the number of common shares remained unchanged in August, with a total of 5,000,000,000 shares, and the total statutory/registered capital was $50,000. The number of issued shares (excluding treasury shares) experienced a slight change, increasing from 1,629,278,889 shares to 1,631,045,869 shares, an increase of 1,766,980 shares. In addition, the report noted that the company issued new shares in August through the exercise of stock options, including pre-IPO stock incentive plans, post-IPO employee share ownership plans, and the 2024 stock plan. The company also corrected some data errors in the previous monthly report. The report was submitted to Hong Kong Exchanges and Clearing Limited by joint company secretary Wang Yanju on September 6, 2024.